Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 3 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 102Thoracic 46Head & Neck 33Breast 31CNS 22Sarcoma 16Genitourinary 11Gynecologic 10Dermatologic 9Tumor-Agnostic 2Other solid neoplasm 2Other 1Endocrine 1Classical hematology 1

Conditions

Thyroid Carcinoma, Anaplastic 1

Interventions

Everolimus 27pembrolizumab 25Temozolomide 24lutetium Lu 177 dotatate 22Nivolumab 18Magnetic Resonance Spectroscopy 18lenvatinib 17cabozantinib 17Cisplatin 16Sunitinib 15Capecitabine 14Bevacizumab 14Specimen Handling 12Sorafenib 12trametinib 10Ipilimumab 10Etoposide 10pasireotide 9dabrafenib 9Paclitaxel 9Carboplatin 8pazopanib 7lanreotide 7Octreotide 7Fluorodeoxyglucose F18 7anlotinib 6Irinotecan 6Injections 6Doxorubicin 6surufatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Surgical Procedures, Operative × Endocrine × Clear all
NCT03565536 2024-04-19

Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer

Fujian Medical University

Phase 2 Completed
18 enrolled
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡